Back to News
Market Impact: 0.15
Kiniksa Pharmaceuticals, Ltd. Appoints Ross Moat as President and Chief Operating Officer
Source: Nasdaq
Management & Governance
Kiniksa Pharmaceuticals International’s Compensation Committee appointed Ross Moat President and Chief Operating Officer, effective immediately on October 17, 2026. The article text is truncated and provides no further details about the appointment.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
KNSA0.10
More News
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- ‘It wasn’t me, and I don’t think it was Elon’: Trump and his cabinet send mixed messages about what led to Ukraine’s Starshield interruptions
- Mark Zuckerberg owns 13% of Meta but controls 61% of its votes. California’s wealth tax would bill him on the 13%
- Volvo Cars posts Q3 loss of 3.7 billion crowns, to cut 2,500 jobs
- Expion Energy amends private placement terms, updates convertible debenture agreement
- Innventure receives Nasdaq notice for minimum bid price non-compliance
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: New Reporting Features and More Sources for Document Search
- How to Evaluate AI Report Writers for Financial Analysis